Further to letter dated 5th November, 2026 and pursuant to Regulation 30 and Schedule Ill of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ennature Bio Pharma has informed that the Board of Directors of the Company in its meeting held today i.e. 12th November, 2026 has considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026. A copy of Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026 along with the Limited Review Report of Statutory Auditors thereon are enclosed. The above said Board Meeting commenced at 12:19 Hrs and concluded at 13:35 Hrs.
The above information is a part of company’s filings submitted to BSE.